Foghorn Therapeutics (FHTX) Research & Development: 2020-2025
Historic Research & Development for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to $20.0 million.
- Foghorn Therapeutics' Research & Development fell 18.98% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.9 million, marking a year-over-year decrease of 14.56%. This contributed to the annual value of $94.5 million for FY2024, which is 13.82% down from last year.
- As of Q3 2025, Foghorn Therapeutics' Research & Development stood at $20.0 million, which was down 8.21% from $21.8 million recorded in Q2 2025.
- Foghorn Therapeutics' Research & Development's 5-year high stood at $30.0 million during Q1 2023, with a 5-year trough of $18.6 million in Q2 2021.
- For the 3-year period, Foghorn Therapeutics' Research & Development averaged around $24.3 million, with its median value being $24.2 million (2023).
- In the last 5 years, Foghorn Therapeutics' Research & Development spiked by 62.79% in 2021 and then decreased by 18.98% in 2025.
- Foghorn Therapeutics' Research & Development (Quarterly) stood at $22.5 million in 2021, then climbed by 25.58% to $28.2 million in 2022, then declined by 14.19% to $24.2 million in 2023, then dropped by 15.27% to $20.5 million in 2024, then fell by 18.98% to $20.0 million in 2025.
- Its last three reported values are $20.0 million in Q3 2025, $21.8 million for Q2 2025, and $21.6 million during Q1 2025.